Clinical Research Support

Research Group Review

The review is to ensure Research Groups prioritize trials for their patient population, to reduce the number of studies that are low-accruing due to competing trials.

Frequently Asked Questions

What studies need Research Group Review?

Any proposed cancer clinical protocol that is subject to SRC review must first receive the endorsement of the relevant Research Group.

Who are the Research Groups?

The Cancer Consortium has 14 established Research Groups:

Research Disease Groups Research Group Director
 1.   Breast Oncology  1.   Julie Gralow
 2.   Gastrointestinal Oncology  2.   Gabriela Chiorean
 3.   GU/Prostate Oncology  3.   Evan Yu
 4.   Gynecologic Oncology  4.   Barbara Goff
 5.   Hematologic Malignancies  5.   Ajay Gopal
 6.   Head and Neck Oncology  6.   Renato Martins
 7.   Lung and Thoracic Oncology  7.   Renato Martins
 8.   RCC/Melanoma  8.   Scott Tykodi
 9.   Neurologic Oncology  9.   Jason Rockhill
 10. Sarcoma  10. Lee Cranmer
 11. Pediatric Oncology  11. Russ Geyer


Research Modality Groups Modality Group Director
 12. Hematopoietic Cell Transplantation (CIM)
 12. Geoffrey Hill
 13. Phase 1 Clinical Trials  13. Kit Wong
 14. Immunotherapy  14. David G. Maloney


What is the process for Research Group Review?

The Director and other leaders of each Research Group are free to use the process that is most appropriate for the group. Research Group reviews are scheduled directly with the groups themselves. Program Assistants in each Research Group can provide the meeting schedule and help with review requirements.

How is Research Group Review documented before a protocol is submitted to the SRC?

At the conclusion of the Research Group review, the Group Director or an authorized proxy must complete a form titled Research Group Information Summary for SRC. The form, managed by Clinical Research Support (CRS), is then given to the investigator or study team to include with the package submitted to CRS.

How do I know which Research Group is most appropriate for my protocol?

In most cases, the affiliation or membership of an investigator to a Research Group will be obvious (i.e., a breast cancer study will be seen by the Breast Oncology Group).  

In cases where the investigator or protocol does not have a clear membership or affiliation with a Research Group, the investigator may complete the Research Group Information Summary for SRC.

In ambiguous cases, please contact CRS at

What if my protocol involves more than one group?

If your protocol involves more than one Research Group, you should consult with the Directors of the most involved groups to decide which one should serve as the primary group.  Only one completed evaluation form is needed for SRC submission.

If a protocol involves both disease and modality groups, both groups should review the protocol.  Evaluation by the Modality Group should be provided to the Disease Group for its consideration. The Disease Group will provide final evaluation for submission to SRC.

Can Research Group Evaluation occur simultaneously with SRC Review?

Research Group Review must occur before scheduling the SRC review. These reviews will be sequential and not concurrent.  A new study submission will not be scheduled for SRC review until the completed Research Group Information Summary for SRC is submitted.

Menu Search